Liminatus Pharma, Inc. (LIMNW) stock

LIMNWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMN

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30

$0.04+0.00 (0.00%)

Close on Oct 30, 2026Market cap $189.39MP/E –Yield –

Liminatus Pharma gross margin

Gross margin is gross profit as a percentage of revenue.

Liminatus Pharma has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.